About us
Introduction
Quality forum
Medicines UK structure
Medicines UK executive team
Our members
Associate members
Disclosure
Our core focus
Patients
Quality
Value
Sustainability
Partnership
Key issues
Introduction
Generic Pricing
Benefits to the NHS
Current supply issues
Patient access
Patient information
Freedom in market pricing
Getting to market
Sustainability
MHRA performance
Better Patent Regulation
Biosimilars
Falsified Medicines Directive
Industry-NHS guidance
About generics
Introduction
Industry overview
The generics industry
Studies on the generic medicines market in the UK
Generics FAQs
News
Current news
Information
Join us
Introduction
Associate Membership
Associate Members
Contact us
About us
Introduction
Quality forum
Medicines UK structure
Medicines UK executive team
Our members
Associate members
Disclosure
Our core focus
Patients
Quality
Value
Sustainability
Partnership
Key issues
Introduction
Generic Pricing
Benefits to the NHS
Current supply issues
Patient access
Patient information
Freedom in market pricing
Getting to market
Sustainability
MHRA performance
Better Patent Regulation
Biosimilars
Falsified Medicines Directive
Industry-NHS guidance
About generics
Introduction
Industry overview
The generics industry
Studies on the generic medicines market in the UK
Generics FAQs
News
Current news
Information
Join us
Introduction
Associate Membership
Associate Members
Contact us
Biosimilars
Back to News index
Delivering a financially sustainable VPAS that supports widened medicines access to patients: Medicines UK's position for the 2024-2028 VPAS negotiations
View the PDF
